A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia
Citations Over TimeTop 14% of 2021 papers
Abstract
Targeting protein-protein interactions (PPIs) with small-molecule inhibitors has become a hotbed of modern drug development. In this review, we describe a new class of PPI inhibitors that block menin from binding to MLL proteins. Menin is encoded by the MEN1 tumor suppressor, but acts as an essential cofactor for MLL/KMT2A-rearranged leukemias. The most promising menin-MLL inhibitors belong to the thienopyrimidine class and have recently entered phase I/II clinical trials for treating acute leukemias characterized by MLL/KMT2A translocations or NPM1 mutations. As single agents, thienopyrimidine compounds eradicate leukemia in a xenograft models of primary leukemic cells belonging to the MLL-rearranged or NPM1-mutant subtypes. These compounds are well tolerated with few or no side effects, which is remarkable given the tumor-suppressor function of menin. The menin-MLL inhibitors highlight how leukemia patients could benefit from a targeted epigenetic therapy with novel PPI inhibitors obtained by directed chemical evolution.
Related Papers
- → Tumor Suppressor Genes: The Puzzle and the Promise(1989)482 cited
- → Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma(1997)3 cited
- [Tumor suppressor gene: implication in the clinical medicine].(1990)
- THE SIGNIFICANCE OF TUMOR SUPRESSOR GENES INACTIVATION IN CARCINOGENESIS OF MULTIPLE PRIMARY NEOPLASM(2000)
- Oncogenes and tumor suppressor genes.(1988)